虽然R-CHOP(利妥昔单抗、环磷酰胺、长春新碱、阿霉素和强的松)免疫化疗方案大大提高了DLBCL的治疗效果,并成为了初治DLBCL的标准治疗方案,但对non-GCB DLBCL的疗效仍然差于GCB DLBCL,non-GCB DLBCL接受R-CHOP治疗后的总体复发率超过30...
GCB patients thus determined was highly significant, with p=0.0026 (log rank) and p=0.043 (log rank) respectively, with a much worse prognosis for ABC patients compared to GCB ones. We then asked whether the ABC and GCB subtypes could be predicted from the DNA methylation profiles of the ...
结论耐RTX的人非GCB型DLBCL细胞株NU-DUL-1-R较亲本株生长速度减慢,细胞周期分布改变,表面CD20抗原表达减少;Aca增强了RTX生物类似药HLX01对非GCB型DLBCL耐药细胞株的杀伤作用,其机制可能与Aca减少IL-17的分泌有关。关键词 利妥昔单抗;生物类...
DLBCL: Frontline Therapy for GCB and ABC Subtypes EP: 3.DLBCL Risk Status and Frontline Treatment Decisions EP: 4.DLBCL: Approaches for Monitoring Frontline Treatment Response EP: 5.DLBCL: Prognosis and Goals of Therapy EP: 6.CD19-Targeted Therapy for DLBCL EP: 7.R/R DLBCL: Treating Fit ...
Patients with germinal center B cell-like (GCB) and non-GCB diffuse large B cell lymphomas (DLBCL) receiving first line therapy have distinct prognosis. We explored the differences in outcome following salvage autologous hematopoietic stem cell (HSC) transplantation between patients with GCB and non...
Because of the poor prognosis of patients with non-GCB DLBCL, especially for those with extranodal disease, this phase 2 study (NCT05498259) was initiated to examine the efficacy and safety of orelabrutinib in addition to R-CHOP in this patient population. ...
The most relevant advancement was the distinction of DLBCL in two subgroups reflecting the postulated cell of origin: germinal center B-cell (GCB) subtype and activated B-cell (ABC) subtype. ABC is characterized by a less favorable prognosis [2]. As this distinction was built on gene-...
be achieved in less than one day, and we repeatedly tested up to 40 patients in parallel), cheap (the cost of one test is less than 5 dollars), and efficient gene expression profiling method to discriminate ABC from GCB DLBCLs and to obtain important information on others prognosis markers...
PrognosisR-CHOPDA-EPOCH-RTherapyThis study was to compare DA-EPOCH-R and R-CHOP regimen as first-line therapy in diffuse large B cell lymphoma (DLBCL) patients, retrospectively. A total of 252 cases treated with R-CHOP and 146 cases who received DA-EPOCH-R were enrolled into this study....
In univariate analysis, the addition of R was associated with a better prognosis in the non-GCB cases (p=0.02), but not in the GCB cases (p=0.3). This survival difference was not solely explained by either Bcl-2 or Bcl-6 expression. The addition of R to CHOP chemotherapy and IPI ...